John Valliant

2019

In 2019, John Valliant earned a total compensation of $1.4M as Chief Executive Officer at Fusion Pharmaceuticals.

Compensation breakdown

Non-Equity Incentive Plan$136,927
Option Awards$835,095
Salary$399,299
Other$28,233
Total$1,399,554

Valliant received $835.1K in option awards, accounting for 60% of the total pay in 2019.

Valliant also received $136.9K in non-equity incentive plan, $399.3K in salary and $28.2K in other compensation.

Rankings

In 2019, John Valliant's compensation ranked 7,675th out of 13,971 executives tracked by ExecPay. In other words, Valliant earned more than 45.1% of executives.

ClassificationRankingPercentile
All
7,675
out of 13,971
45th
Division
Manufacturing
2,993
out of 5,701
48th
Major group
Chemicals And Allied Products
1,125
out of 2,200
49th
Industry group
Drugs
959
out of 1,886
49th
Industry
Biological Products, Except Diagnostic Substances
221
out of 389
43rd
Source: SEC filing on April 27, 2021.

Valliant's colleagues

We found two more compensation records of executives who worked with John Valliant at Fusion Pharmaceuticals in 2019.

2019

John Crowley

Fusion Pharmaceuticals

Chief Financial Officer

2019

Eric Burak

Fusion Pharmaceuticals

Chief Scientific Officer

News

In-depth

You may also like